Cure SMA Canada – Patient Community Announcement
Cure SMA Canada is very happy to announce that the pCPA, provinces and Biogen have FINALLY come to an agreement for the first submission of Nusinersen/Spinraza for review. We are pleased to confirm that all patients with type 1 in all jurisdictions in Canada will be able to access treatment through their public drug plans.
In addition, Biogen is offering coverage of type 2 and 3 patients under an Urgent Access Program. Please see details within their patient community statement through the link below.
We at Cure SMA Canada will continue our advocacy campaign to ensure the remainder of our patients who are not able to access treatment through their public drug plans, are not forgotten. We are quite hopeful that Biogen’s resubmission of data for review will result in a positive recommendation. The response to this second submission should be received in January 2019.
We celebrate this victory, which offers coverage for our type 1 patients. We must, however, continue as a cohesive community to ensure that all of our patients receive the same wonderful news. We will remain strong and determined to provide the input that gives insight to the decision makers to support our remaining patients.
Thank you to all of our patients, families and supporters, we have worked hard for these results! We should all feel proud of our accomplishments, together we will see this through for all of our patients!
